Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.

NCT02670083 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02670083
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02670083 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease.
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Terminated
Start date
March 22, 2016
Completion date
May 31, 2019
Enrollment
813 (actual)
Sites
196

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease